Patents by Inventor Ruijing Huang

Ruijing Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HM-3 fusion protein and application thereof
    Patent number: 11655308
    Abstract: The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)n-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3)n, or (HM-3)n-Linker-Fc(IgG)-Linker-(HM-3)n. The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: May 23, 2023
    Assignee: TASLY BIOPHARMACEUTICALS CO., LTD.
    Inventors: Ruijing Huang, Baoqing Fan, Jian Li, Xiaohui Ma, Yibo Wang, Lihua Zhang, Xiaodan Cao, Wenlei Li, Pengyin Wang, Yan Chen
  • HM-3 FUSION PROTEIN AND APPLICATION THEREOF
    Publication number: 20210009717
    Abstract: The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)n-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3)n, or (HM-3)n-Linker-Fc(IgG)-Linker-(HM-3)n. The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.
    Type: Application
    Filed: November 23, 2018
    Publication date: January 14, 2021
    Inventors: Ruijing HUANG, Baoqing FAN, Jian LI, Xiaohui MA, Yibo WANG, Lihua ZHANG, Xiaodan CAO, Wenlei LI, Pengyin WANG, Yan CHEN
  • METHOD OF TREATING NASH USING A LONG-ACTING MUTANT HUMAN FIBROBLAST GROWTH FACTOR
    Publication number: 20190367574
    Abstract: The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPEG-CH2—N?H-mFGF21, wherein mFGF21 consists of SEQ ID NO:1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.
    Type: Application
    Filed: July 23, 2019
    Publication date: December 5, 2019
    Inventors: Jian Li, Jun Han, Xiaohui Ma, Ping Tai, Genbei Wang, Xiaodan Cao, Ruijing Huang, Yongjie Jin, Jing Li, Chen Chen, Guoyong Jia, Yuanyuan Wang